EP0514067A1 - Composition cosmétique - Google Patents
Composition cosmétique Download PDFInfo
- Publication number
- EP0514067A1 EP0514067A1 EP19920304041 EP92304041A EP0514067A1 EP 0514067 A1 EP0514067 A1 EP 0514067A1 EP 19920304041 EP19920304041 EP 19920304041 EP 92304041 A EP92304041 A EP 92304041A EP 0514067 A1 EP0514067 A1 EP 0514067A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- composition according
- citric acid
- group
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 239000002537 cosmetic Substances 0.000 title description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 61
- 239000000516 sunscreening agent Substances 0.000 claims abstract description 30
- 230000000475 sunscreen effect Effects 0.000 claims abstract description 20
- -1 citric acid ester Chemical class 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims abstract description 12
- 230000000699 topical effect Effects 0.000 claims abstract description 10
- 230000000254 damaging effect Effects 0.000 claims abstract description 8
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 6
- 125000003118 aryl group Chemical group 0.000 claims abstract description 6
- 150000005691 triesters Chemical class 0.000 claims abstract description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 5
- 125000005354 acylalkyl group Chemical group 0.000 claims abstract description 3
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 44
- 239000004408 titanium dioxide Substances 0.000 claims description 22
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 44
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 17
- 239000003995 emulsifying agent Substances 0.000 description 16
- 239000006071 cream Substances 0.000 description 13
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229930002330 retinoic acid Natural products 0.000 description 9
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 8
- 229960003471 retinol Drugs 0.000 description 8
- 235000020944 retinol Nutrition 0.000 description 8
- 239000011607 retinol Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 230000003810 hyperpigmentation Effects 0.000 description 5
- 208000000069 hyperpigmentation Diseases 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000008832 photodamage Effects 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- OJIBJRXMHVZPLV-UHFFFAOYSA-N 2-methylpropyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(C)C OJIBJRXMHVZPLV-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical class OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical group C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010037867 Rash macular Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HDDLVZWGOPWKFW-UHFFFAOYSA-N Trimethyl citrate Natural products COC(=O)CC(O)(C(=O)OC)CC(=O)OC HDDLVZWGOPWKFW-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940048299 acetylated lanolin alcohols Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- ZGISOPBIAXHOTQ-OUGXGHBNSA-N all-trans-retinyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C ZGISOPBIAXHOTQ-OUGXGHBNSA-N 0.000 description 1
- XJKITIOIYQCXQR-SCUNHAKFSA-N all-trans-retinyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XJKITIOIYQCXQR-SCUNHAKFSA-N 0.000 description 1
- AWGMQQGZWRIUJI-UBMBPVGBSA-N all-trans-retinyl octanoate Chemical compound CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AWGMQQGZWRIUJI-UBMBPVGBSA-N 0.000 description 1
- FXKDHZXYYBPLHI-TUTABMRPSA-N all-trans-retinyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FXKDHZXYYBPLHI-TUTABMRPSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- KMJRBSYFFVNPPK-UHFFFAOYSA-K aluminum;dodecanoate Chemical compound [Al+3].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O KMJRBSYFFVNPPK-UHFFFAOYSA-K 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ANXXYABAFAQBOT-UHFFFAOYSA-N dodecyl-methyl-bis(trimethylsilyloxy)silane Chemical group CCCCCCCCCCCC[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C ANXXYABAFAQBOT-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 229910000286 fullers earth Inorganic materials 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- OXGBCSQEKCRCHN-UHFFFAOYSA-N octadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCC(C)O OXGBCSQEKCRCHN-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940071220 retinyl linoleate Drugs 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Definitions
- the invention relates to a composition for topical application to human skin in order to promote the repair of photo-damaged skin and/or to reduce or prevent the damaging effects of ultra-violet light on skin.
- the invention also relates to the use of such compositions in the repair of photo-damaged skin and in the prevention of damage to skin due to exposure to ultra-violet light.
- Skin blotchiness or mottling which accompanies photo-ageing results from changes in the melanocytes within the population of epidermal cells.
- These pigment producing cells which unlike the keratinocytes remain at the base of the epidermis, lose their normal regulation process with ageing and produce excess pigment. This leads to the formation of dense perinuclear clumps of melanin in slowly turning over keratinocytes within the epidermis, and areas of hyperpigmentation or 'age spots' develop.
- certain skin lightening agents such as kojic acid, hydroquinone or ascorbic acid are effective by inhibiting the formation of melanin.
- Vitamin A acid retinoic acid
- Vitamin A acid is beneficial in hyperpigmentation problems by normalising the melanocyte population.
- Vitamin A acid prevents accumulation of pigment within the more rapidly dividing and migrating keratinocytes. Vitamin A acid also enhances the pigment reducing potential of conventional skin lightening agents.
- Vitamin A acid does however have a major drawback in that it is a skin irritant, and can accordingly damage the skin. Its recommended use for example as a prescription drug in the treatment of acne involves careful control, such that excessive doses are avoided in order to restrict the side effects which can occur with skin. By the same token, the use of Vitamin A acid in the treatment or prevention of photo-damaged skin is severely limited by these side effects.
- esters of citric acid especially tributyl citrate are particularly effective in this respect.
- Use of such esters is advantageous since they have a history of safe use, for example as plasticizers, including in plastics as used in intravenous fluid tubings.
- the invention is accordingly concerned with the use of esters of citric acid in the treatment of photo-damaged and/or hyperpigmented skin, and in slowing down the ageing process generally.
- the invention also concerns compositions for topical application to human skin to reduce damaging effects of ultra-violet light on skin, comprising a citric acid ester in combination with a sunscreen material.
- the invention provides a composition suitable for topical application to human skin in order to reduce the damaging effects of ultra-violet light on skin, which composition comprises:
- the present invention provides use of a triester of citric acid having the structure (1) as defined above as an agent for reducing the damaging effects of ultraviolet light on skin, in a topical composition comprising a major proportion of a cosmetically acceptable vehicle for the ester of citric acid.
- the invention concerns a composition
- a composition comprising an organic ester of citric acid, together with a suitable cosmetically acceptable vehicle and a sunscreen agent, which acts to retard the ageing process of the skin, when applied topically thereto.
- the sunscreen agent in the composition assists to prevent skin blotchiness and mottling due to hyperpigmentation and generally effect an overall improvement in skin texture with reduction in fine wrinkling and improved skin colour.
- Co-formulation with a sunscreen is also believed to enhance synergistically the photo-stability and activity of the ester of citric acid within the formulation and also prevent further actinic damage to all epidermal cells and dermal tissue.
- composition according to the invention comprises a triester of citric acid or mixtures thereof, each having the structure (1).
- the preferred esters of citric acid are those where the R1, R2 and R3 groups in structure (1) are each alkyl groups, examples of which include: trimethyl citrate triethyl citrate tri-n-propyl citrate tri-n-butyl citrate trihexyl citrate trioctyl citrate tridodecyl citrate trihexadecyl citrate triphenyl citrate tri-2-ethylhexyl citrate.
- the above preferred trialkyl citrates can also be acylated at the 2 position, further to enhance their lipophilic character, and examples of these are: 2-acetyl trimethyl citrate 2-acetyl triethyl citrate 2-acetyl tri-n-propyl citrate 2-acetyl tri-n-butyl citrate 2-oleoyl tri-n-butyl citrate 2-0-methyl tri-n-butyl citrate 2-0-ethyl tri-n-butyl citrate 2-0-isopropyl tri-n-butyl citrate.
- the most preferred citrates are those in which R4 is an acyl group having from 2 to 4 carbon atoms, or an alkyl group having from 1 to 4 carbon atoms.
- the most preferred ester of citric acid is tri-n-butyl citrate or its acylated derivative.
- the amount of the ester of citric acid having the structure (1), present in the composition according to the invention is from 0.01 to 20%, particularly from 0.1 to 10% 5 by weight of the composition, preferably more than 0.5%, most preferably at least 1% and typically less than 6%.
- composition according to the invention also comprises a cosmetically acceptable vehicle to act as a dilutant, dispersant or carrier for other materials present in the composition, so as to facilitate their distribution when the composition is applied to the skin.
- Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners and powders.
- Emollients such as stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate,
- the cosmetically acceptable vehicle will usually form from 10 to 99.9%, preferably from 50 to 99% by weight of the emulsion, and can, in the absence of other cosmetic adjuncts, form the balance of the composition.
- composition of the invention includes an effective amount of a sunscreen agent which may comprise an organic sunscreen further to enhance synergistically the benefit of the composition in providing protection from the harmful effects of excessive exposure to sunlight.
- a sunscreen agent which may comprise an organic sunscreen further to enhance synergistically the benefit of the composition in providing protection from the harmful effects of excessive exposure to sunlight.
- Suitable organic sunscreens when required, include those set out in Table 1 below, and mixtures thereof.
- composition of the invention can accordingly comprise from 0.1 to 10%, preferably from 1 to 5%, suitably 1.5 to 4.5% by weight of an organic sunscreen material.
- the sunscreen agent according to the invention can optionally comprise an inorganic sunscreen, such as ultrafine titanium dioxide in either of two forms, namely water-dispersible titanium dioxide and oil-dispersible titanium dioxide.
- an inorganic sunscreen such as ultrafine titanium dioxide in either of two forms, namely water-dispersible titanium dioxide and oil-dispersible titanium dioxide.
- Water-dispersible titanium dioxide is ultrafine titanium dioxide, the particles of which are uncoated or which are coated with a material to impart a hydrophilic surface property to the particles.
- a material to impart a hydrophilic surface property examples include aluminium oxide and aluminium silicate.
- Oil-dispersible titanium dioxide is ultrafine titanium dioxide, the particles of which exhibit a hydrophobic surface property, and which, for this purpose, can be coated with metal soaps such as aluminium stearate, aluminium laurate or zinc stearate, or with organosilicone compounds.
- ultra titanium dioxide particles of titanium dioxide having an average particle size of less than 100nm, preferably 70nm or less, more preferably from 10 to 40nm and most preferably from 15 to 25nm.
- the weight ratio of water-dispersible titanium dioxide to oil-dispersible titanium dioxide should be from 1:4 to 4:1, preferably from 1:2 to 2:1 and ideally about equal weight proportions.
- the total amount of titanium dioxide that can optionally can be incorporated in the composition according to the invention is from 1 to 25%, preferably from 2 to 10% and ideally from 3 to 7% by weight of the composition.
- the emulsion of the invention optionally can comprise an inorganic sunscreen in addition to ultrafine titanium dioxide as herein defined.
- the inorganic sunscreen has an average particle size of less then 70nm, preferably from 10 to 40 nm and most preferably from 15 to 25nm.
- examples of other inorganic sunscreens include: zinc oxide, iron oxide, and silica, such as fumed silica, having an average particle size of less than 100nm, typically from 1nm to 100nm.
- silica when used as an ingredient in the emulsion according to the invention can provide protection from infra-red radiation.
- the composition includes from 1 to 25%, typically from 2 to 10% and most preferably from 3 to 7% by weight of inorganic sunscreens.
- composition according to the invention is an emulsion, in which case an oil or oily material will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophilic-lyophilic balance (HLB) of the emulsifier employed.
- HLB hydrophilic-lyophilic balance
- composition according to the invention can optionally comprise one or more oils or other materials having the properties of an oil.
- oils examples include mineral oil and vegetable oils, and oil materials, such as those already proposed herein as emollients.
- oils or oily materials include silicone oils, both volatile and non-volatile, such as polydimethyl siloxanes.
- Oily vehicles in which the esters are soluble or miscible, such that a composition is formed which does not separate into two or more phases on standing are particularly advantageous. In such compositions penetration of the citric acid ester into the skin can thereby be expected to be enhanced.
- the oil or oily material when present for the purposes for forming an emulsion, will normally form up to 90%, preferably from 10 to 80% by volume of the composition.
- composition according to the invention can also optionally comprise one or more emulsifiers the choice of which will normally determine whether a water-in-oil or and oil-in-water emulsion is formed.
- the chosen emulsifier or emulsifiers should normally have an average HLB value of from 1 to 6.
- a chosen emulsifier or emulsifiers should have an average HLB value of >6.
- Suitable emulsifiers are set below in Table 1 in which the chemical name of the emulsifiers is given together with an example of a trade name as commercially available, and the average HLB value.
- the amount of emulsifier or mixtures thereof, that optionally can be incorporated in the composition of the invention is from 1 to 50%, preferably from 2 to 20% and most preferably from 2 to 10% by weight of the composition.
- composition of the invention can also comprise water, usually up to 80%, preferably from 5 to 80% by volume.
- composition of the invention can also optionally comprise a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
- a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
- the silicone surfactant is a high molecular weight polymer of dimethyl polysiloxane with polyoxyethylene and/or polyoxypropylene side chains having a molecular weight of from 10,000 to 50,000 and having the structure: where the groups R′ and R ⁇ are each chosen from -H, C1 ⁇ 18 alkyl and - [CH2 CH2 O] a
- the dimethyl polysiloxane polymer is one in which:
- a particularly preferred dimethyl polysiloxane polymer is one in which:
- the dimethyl polysiloxane polymer is conveniently provided as a dispersion in a volatile siloxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymer and from 80 to 99% by volume of the volatile siloxane.
- the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siloxane.
- volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyl siloxane (pentamer and/or hexamer).
- a particularly preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C Formulation Aid available from DOW CORNING.
- Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.
- the amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.
- composition according to the invention optionally can also comprise an additional anti-ageing active such as retinol (Vitamin A) and/or derivative thereof, further to enhance repair of photo damage to skin following exposure to ultra-violet light.
- an additional anti-ageing active such as retinol (Vitamin A) and/or derivative thereof, further to enhance repair of photo damage to skin following exposure to ultra-violet light.
- examples of derivatives of retinol include: Retinyl acetate Retinyl butyrate Retinyl propionate Retinyl octanoate Retinyl laurate Retinyl palmitate Retinyl oleate, and Retinyl linoleate.
- the amount of retinol, or a cosmetically acceptable derivative thereof, when present in the composition according to the invention is from 0.01 to 10% and preferably 0.1 to 5% by weight of the composition.
- composition according to the invention optionally can also comprise a tocopherol (vitamin E group), as an antioxidant for retinol, or a derivative, when present in the composition, and to limit oxidative damage to skin.
- vitamin E group comprises ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol and ⁇ -tocopherol.
- the amount of a tocopherol, when present in the composition according to the invention, is from 0.0001 to 20%, preferably from 0.001 to 10% by weight of the composition.
- adjuncts examples include preservatives, such as para-hydroxy benzoate esters; antioxidants, such butyl hydroxy toluene; humectants, such as glycerol, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, such as PEG 200-600; buffers, such as lactic acid together with a base such as triethanolamine or sodium hydroxide; waxes, such as beeswax, ozokerite wax, paraffin wax; plant extracts, such as Aloe vera, cornflower, witch hazel, elderflower, cucumber; thickeners; activity enhancers; colourants; and perfumes.
- Cosmetic adjuncts can form the balance of the composition.
- the composition according to the invention is intended primarily as a skin care product for topical application to human skin to prevent photo-damage to skin, which can result from exposure to sunlight, and which can retard natural skin ageing.
- the composition can also be used to reduce skin blotchiness and mottling due to hyperpigmentation, to improve skin texture with reduction in fine wrinkling and otherwise to improve skin colour and texture.
- the composition when topically applied to skin, is useful in the prevention of actinic damage to all epidermal cells and dermal tissue.
- a small quantity of the composition for example from 1 to 5ml, is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device.
- the topical skin treatment composition of the invention can be formulated as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas, or above.
- the composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer.
- a lotion or fluid cream can be packaged in a bottle or a roll-ball applicator or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
- the composition When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
- the invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.
- a base composition (cream) was prepared as a vehicle for retinoic acid, retinol or tri-n-butyl citrate, to study changes to skin, if any, attributable to these substances.
- the base composition (cream) contained the following ingredients:
- Test creams were then prepared by addition to the base cream of retinoic acid, retinol or tri-n-butyl citrate.
- the test and control (i.e. no additives) creams were applied to the depilated backs of albino mice, albino guinea pigs and black mice (50 mg per animal per application). A total of from 4 to 30 applications were made. Evaluations were performed at the end of the treatment periods by gross morphology and microscopic anatomy. The results are tabulated below:
- Tri-n-butyl citrate caused histological changes in the epidermis that were similar to that caused by retinol. This indicates that the effects would be beneficial and that tri-n-butyl citrate would have antiageing properties. No irritant effects were observed even on prolonged application.
- the invention is further illustrated by the following examples; in each formulation, the titanium dioxide employed was ultrafine titanium dioxide having a mean particle size of from 15 to 25nm.
- This example illustrates a lotion according to the invention.
- This example illustrates a fluid cream according to the invention.
- This example illustrates a cream according to the invention.
- This example illustrates a lotion according to the invention.
- This example illustrates a cream in accordance with the invention.
- This example also illustrates a cream in accordance with the invention.
- This example illustrates a lotion according to the invention.
- This example illustrates a lotion according to the invention.
- This example illustrates a lotion according to the invention.
- This example illustrates an anhydrous formulation for addition of sunscreen in accordance with the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9109965 | 1991-05-07 | ||
GB919109965A GB9109965D0 (en) | 1991-05-07 | 1991-05-07 | Cosmetic composition |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0514067A1 true EP0514067A1 (fr) | 1992-11-19 |
EP0514067B1 EP0514067B1 (fr) | 1997-08-27 |
EP0514067B2 EP0514067B2 (fr) | 2004-07-14 |
Family
ID=10694655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92304041A Expired - Lifetime EP0514067B2 (fr) | 1991-05-07 | 1992-05-05 | Composition cosmétique |
Country Status (11)
Country | Link |
---|---|
US (1) | US5244665A (fr) |
EP (1) | EP0514067B2 (fr) |
JP (1) | JPH0737376B2 (fr) |
AT (1) | ATE157245T1 (fr) |
AU (1) | AU652047B2 (fr) |
BR (1) | BR9201698A (fr) |
CA (1) | CA2067888C (fr) |
DE (1) | DE69221766T3 (fr) |
ES (1) | ES2106828T5 (fr) |
GB (1) | GB9109965D0 (fr) |
ZA (1) | ZA923312B (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0691126A1 (fr) * | 1994-07-05 | 1996-01-10 | Beiersdorf Aktiengesellschaft | Compositions cosmétiques ou dermatologiques contenant alpha-hydroxy acides et/ou acides cétoniques et pigments inorganiques |
WO1996003110A1 (fr) * | 1994-07-22 | 1996-02-08 | Coletica | Acide hydroxyle lipophile, son utilisation en cosmetique et en pharmacie, et son procede de preparation |
WO1996038125A1 (fr) * | 1995-06-02 | 1996-12-05 | Beiersdorf Ag | COMPOSITIONS COSMETIQUES OU DERMATOLOGIQUES CONTENANT DES OLIGOMERES OU DES POLYMERES D'ACIDES α-HYDROXYCARBOXYLIQUES |
US6013247A (en) * | 1996-07-29 | 2000-01-11 | L'oreal | Composition for protecting the skin or the hair, containing nanopigments and a solid elastomeric polyorganosiloxane combined with a fatty phase |
EP0987005A2 (fr) * | 1998-09-18 | 2000-03-22 | Beiersdorf Aktiengesellschaft | Systèmes en dispersion fine, sans émulsifiants, de type huile-dans-eau ou eau-dans-huile |
US6080390A (en) * | 1997-08-27 | 2000-06-27 | Revlon Consumer Products Corporation | Moisturizing cosmetic stick compositions |
WO2000061078A2 (fr) * | 1999-04-10 | 2000-10-19 | Cognis Deutschland Gmbh | Agents photoprotecteurs |
WO2003075880A1 (fr) * | 2002-03-11 | 2003-09-18 | Unilever Plc | Compositions cosmetiques renfermant des triesters d'acide citrique |
WO2008063441A2 (fr) * | 2006-11-16 | 2008-05-29 | The Procter & Gamble Company | Composition pour soins personnels |
US10245220B2 (en) | 2015-07-22 | 2019-04-02 | Biosynthis | Process for pongamol enrichment of karanja oil |
US20200289382A1 (en) * | 2017-09-11 | 2020-09-17 | Oleon Nv | Emulsifying combination for obtaining low viscosity water-in-oil emulsions |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733531A (en) * | 1991-02-05 | 1998-03-31 | Sunsmart, Inc. | Composite UV sunblock compositions |
EP0608433B1 (fr) * | 1992-07-13 | 2004-05-19 | Shiseido Company, Ltd. | Composition de preparation dermatologique |
JP3566739B2 (ja) * | 1993-09-30 | 2004-09-15 | 三省製薬株式会社 | 皮膚外用剤の安定化方法 |
US6068834A (en) | 1994-03-04 | 2000-05-30 | The Procter & Gamble Company | Skin lightening compositions |
US5451405A (en) * | 1994-04-25 | 1995-09-19 | Chesebrough-Pond's Usa Co. | Skin treatment composition |
CA2130967C (fr) * | 1994-08-26 | 2003-10-28 | Dorothy Mccuaig | Composition desodorisante a longue duree de vie |
US5874463A (en) | 1994-10-24 | 1999-02-23 | Ancira; Margaret | Hydroxy-kojic acid skin peel |
ES2177680T3 (es) * | 1994-12-20 | 2002-12-16 | Oreal | Composicion de maquillaje revitalizante. |
US5618850A (en) * | 1995-03-09 | 1997-04-08 | Focal, Inc. | Hydroxy-acid cosmetics |
FR2735688B1 (fr) * | 1995-06-26 | 1997-08-14 | Oreal | Utilisation en association d'un alpha-hydroxyacide et d'un oxyde de titane pour le blanchiment de la peau |
US5571518A (en) | 1995-10-30 | 1996-11-05 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions containing tricholine citrate |
US5725845A (en) * | 1995-11-03 | 1998-03-10 | Revlon Consumer Products Corporation | Transfer resistant cosmetic stick compositions with semi-matte finish |
US5690918A (en) * | 1995-12-19 | 1997-11-25 | Maybelline, Inc. | Solvent-based non-drying lipstick |
US5885595A (en) * | 1996-05-13 | 1999-03-23 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic composition with a retinol fatty acid ester |
US5855877A (en) * | 1996-09-06 | 1999-01-05 | Colgate-Palmolive Company | Non-aqueous antiperspirant composition |
US5874094A (en) * | 1997-08-05 | 1999-02-23 | Costello; Jeremiah | Cream formulation for topical application |
US20030124153A1 (en) * | 1997-08-27 | 2003-07-03 | Revlon Consumer Products Corporation | Cosmetic Stick Compositions With Improved Application |
US6217852B1 (en) * | 1998-08-15 | 2001-04-17 | Skinnovative Dermatologic Concepts, L.L.C. | Personal cleansing compositions having photoprotective agents |
US6165450A (en) * | 1999-05-03 | 2000-12-26 | Em Industries, Inc. | Sprayable sunscreen compositions |
DE10000210A1 (de) * | 2000-01-05 | 2001-07-12 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen vom Typ Öl-in-Wasser |
US6355280B1 (en) * | 2000-02-28 | 2002-03-12 | I.M.S. Cosmetics | Composition for reducing cell apoptosis containing avocado and soybean lipid unsaponifiables |
JP4406855B2 (ja) * | 2000-03-17 | 2010-02-03 | 株式会社ビメーク | 化粧料 |
US20070166255A1 (en) * | 2004-11-22 | 2007-07-19 | Gupta Shyam K | Treatment of Topical Discomforts Including Acne, Sunburn, Diaper Rash, Wound, Wrinkles and Dandruff/Hair Loss by Natural Lignans via Fatty Acid Desaturase Inhibition |
CN101123937B (zh) * | 2005-09-09 | 2012-10-31 | 宝洁公司 | 包含多层的固体护肤组合物 |
US20080160097A1 (en) | 2006-12-28 | 2008-07-03 | Avon Products, Inc. | Method for imparting a cosmetic or therapeutic benefit to a topical surface and process for making |
WO2015145464A2 (fr) * | 2014-03-27 | 2015-10-01 | Kancor Ingredients Ltd | Composition d'écran solaire photostable pour application topique |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1437366A (fr) * | 1963-03-11 | 1966-05-06 | Savon, produit cosmétique et produits analogues | |
EP0006232A1 (fr) * | 1978-06-19 | 1980-01-09 | Henkel Kommanditgesellschaft auf Aktien | L'utilisation comme déodorants d'une combinaison de sels d'aluminium acides, astringents, avec des esters d'acide citrique, d'acide acétylcitrique, ou d'un acide mono- ou dibasique aliphatique hydroxycarbonique et avec un antioxydant |
EP0347664A1 (fr) * | 1988-06-18 | 1989-12-27 | Henkel Kommanditgesellschaft auf Aktien | Compositions cosmétiques et pharmaceutiques pour application topique |
EP0357186A2 (fr) * | 1988-06-25 | 1990-03-07 | Beecham Group Plc | Compositions pour les soins de la peau et des cheveux |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE632886A (fr) * | 1962-06-01 | |||
US3214338A (en) * | 1964-07-31 | 1965-10-26 | Ehrlich Joseph Ronald | Medicament releasing film-forming ointments and process of making |
DE2826758A1 (de) * | 1978-06-19 | 1979-12-20 | Henkel Kgaa | Verwendung einer kombination von estern der citronensaeure und/oder acetylcitronensaeure mit antioxidantien als deodorantien |
US4515810A (en) * | 1983-10-06 | 1985-05-07 | American Cyanamid Company | Composition of matter |
US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
EP0260859A1 (fr) * | 1986-09-19 | 1988-03-23 | SMITH & NEPHEW UNITED, INC. | Préparation médicinale pour la peau |
US4866203A (en) * | 1987-03-10 | 1989-09-12 | Lever Brothers Company | Method for synthesizing a salt of a monoester of citric acid |
US5047166A (en) * | 1987-03-10 | 1991-09-10 | Lever Brothers Company, Division Of Conopco, Inc. | Skin treatment composition containing monoester of citric acid |
US4866202A (en) * | 1987-03-10 | 1989-09-12 | Lever Brothers Company | Method for synthesizing a salt of a monoester of citric acid |
US4847071A (en) * | 1987-10-22 | 1989-07-11 | The Procter & Gamble Company | Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent |
US5089531A (en) * | 1989-07-07 | 1992-02-18 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions incorporating a salt of monoester of citric acid and a method for synthesizing the monoester |
-
1991
- 1991-05-07 GB GB919109965A patent/GB9109965D0/en active Pending
-
1992
- 1992-05-01 CA CA002067888A patent/CA2067888C/fr not_active Expired - Fee Related
- 1992-05-01 AU AU15990/92A patent/AU652047B2/en not_active Ceased
- 1992-05-05 ES ES92304041T patent/ES2106828T5/es not_active Expired - Lifetime
- 1992-05-05 AT AT92304041T patent/ATE157245T1/de not_active IP Right Cessation
- 1992-05-05 EP EP92304041A patent/EP0514067B2/fr not_active Expired - Lifetime
- 1992-05-05 DE DE69221766T patent/DE69221766T3/de not_active Expired - Fee Related
- 1992-05-06 BR BR929201698A patent/BR9201698A/pt not_active IP Right Cessation
- 1992-05-06 US US07/879,657 patent/US5244665A/en not_active Expired - Lifetime
- 1992-05-07 ZA ZA923312A patent/ZA923312B/xx unknown
- 1992-05-07 JP JP4115016A patent/JPH0737376B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1437366A (fr) * | 1963-03-11 | 1966-05-06 | Savon, produit cosmétique et produits analogues | |
EP0006232A1 (fr) * | 1978-06-19 | 1980-01-09 | Henkel Kommanditgesellschaft auf Aktien | L'utilisation comme déodorants d'une combinaison de sels d'aluminium acides, astringents, avec des esters d'acide citrique, d'acide acétylcitrique, ou d'un acide mono- ou dibasique aliphatique hydroxycarbonique et avec un antioxydant |
EP0347664A1 (fr) * | 1988-06-18 | 1989-12-27 | Henkel Kommanditgesellschaft auf Aktien | Compositions cosmétiques et pharmaceutiques pour application topique |
EP0357186A2 (fr) * | 1988-06-25 | 1990-03-07 | Beecham Group Plc | Compositions pour les soins de la peau et des cheveux |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 13, no. 199 (C-594)(3547) 11 May 1989 & JP-A-1 019 012 ( KANEBO ) 23 January 1989 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0691126A1 (fr) * | 1994-07-05 | 1996-01-10 | Beiersdorf Aktiengesellschaft | Compositions cosmétiques ou dermatologiques contenant alpha-hydroxy acides et/ou acides cétoniques et pigments inorganiques |
US6039961A (en) * | 1994-07-22 | 2000-03-21 | Coletica | Lipophilic hydroxylated acid, its use in cosmetics and pharmacy, and its process of preparation |
WO1996003110A1 (fr) * | 1994-07-22 | 1996-02-08 | Coletica | Acide hydroxyle lipophile, son utilisation en cosmetique et en pharmacie, et son procede de preparation |
US5869069A (en) * | 1994-07-22 | 1999-02-09 | Coletica | Lipophilic hydroxylated acid, its use in cosmetics and pharmacy, and its process of preparation |
WO1996038125A1 (fr) * | 1995-06-02 | 1996-12-05 | Beiersdorf Ag | COMPOSITIONS COSMETIQUES OU DERMATOLOGIQUES CONTENANT DES OLIGOMERES OU DES POLYMERES D'ACIDES α-HYDROXYCARBOXYLIQUES |
US6261542B1 (en) | 1996-07-29 | 2001-07-17 | L'oreal | Composition for protecting the skin or the hair, containing nanopigments and a solid elastomeric polyorganosiloxane combined with a fatty phase |
US6013247A (en) * | 1996-07-29 | 2000-01-11 | L'oreal | Composition for protecting the skin or the hair, containing nanopigments and a solid elastomeric polyorganosiloxane combined with a fatty phase |
US6080390A (en) * | 1997-08-27 | 2000-06-27 | Revlon Consumer Products Corporation | Moisturizing cosmetic stick compositions |
US6579529B2 (en) | 1998-09-18 | 2003-06-17 | Beiersdorf Ag | Emulsifier-free finely disperse systems of the oil-in-water and water-in-oil type |
US6692755B2 (en) | 1998-09-18 | 2004-02-17 | Beiersdorf Ag | Emulsifier-free finely disperse systems of the oil-in-water and water-in-oil type |
EP0987005A2 (fr) * | 1998-09-18 | 2000-03-22 | Beiersdorf Aktiengesellschaft | Systèmes en dispersion fine, sans émulsifiants, de type huile-dans-eau ou eau-dans-huile |
EP0987005A3 (fr) * | 1998-09-18 | 2001-10-31 | Beiersdorf Aktiengesellschaft | Systèmes en dispersion fine, sans émulsifiants, de type huile-dans-eau ou eau-dans-huile |
WO2000061078A3 (fr) * | 1999-04-10 | 2001-03-29 | Cognis Deutschland Gmbh | Agents photoprotecteurs |
US6569410B1 (en) | 1999-04-10 | 2003-05-27 | Cognis Deutschland Gmbh | Sun protection compositions containing UV protection factors and esters of hydroxycarboxylic acids and alk(en)yl oligoglycosides |
WO2000061078A2 (fr) * | 1999-04-10 | 2000-10-19 | Cognis Deutschland Gmbh | Agents photoprotecteurs |
WO2003075880A1 (fr) * | 2002-03-11 | 2003-09-18 | Unilever Plc | Compositions cosmetiques renfermant des triesters d'acide citrique |
WO2008063441A2 (fr) * | 2006-11-16 | 2008-05-29 | The Procter & Gamble Company | Composition pour soins personnels |
WO2008063441A3 (fr) * | 2006-11-16 | 2008-08-21 | Procter & Gamble | Composition pour soins personnels |
US10245220B2 (en) | 2015-07-22 | 2019-04-02 | Biosynthis | Process for pongamol enrichment of karanja oil |
US20200289382A1 (en) * | 2017-09-11 | 2020-09-17 | Oleon Nv | Emulsifying combination for obtaining low viscosity water-in-oil emulsions |
Also Published As
Publication number | Publication date |
---|---|
ES2106828T3 (es) | 1997-11-16 |
AU652047B2 (en) | 1994-08-11 |
ES2106828T5 (es) | 2005-03-16 |
ZA923312B (en) | 1993-11-08 |
JPH05124946A (ja) | 1993-05-21 |
JPH0737376B2 (ja) | 1995-04-26 |
DE69221766T2 (de) | 1998-01-29 |
CA2067888C (fr) | 1997-06-03 |
AU1599092A (en) | 1992-11-12 |
US5244665A (en) | 1993-09-14 |
ATE157245T1 (de) | 1997-09-15 |
CA2067888A1 (fr) | 1992-11-08 |
EP0514067B1 (fr) | 1997-08-27 |
DE69221766T3 (de) | 2004-09-30 |
DE69221766D1 (de) | 1997-10-02 |
BR9201698A (pt) | 1992-12-15 |
GB9109965D0 (en) | 1991-07-03 |
EP0514067B2 (fr) | 2004-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0514067B1 (fr) | Composition cosmétique | |
EP0666735B1 (fr) | Compositions cosmetiques contenant du retinol | |
EP0512814A1 (fr) | Composition cosmétique | |
EP0725623B1 (fr) | Composition cosmetique comprenant une hydrocalchone et du retinol ou un derive de celui-ci | |
EP0456459B1 (fr) | Compositions cosmétique | |
EP0431755B1 (fr) | Composition cosmétique | |
KR100455470B1 (ko) | 피토스테롤 조성물의 국소 적용을 통한 포유류 케라틴조직 상태의 조절 방법 | |
US5980904A (en) | Skin whitening composition containing bearberry extract and a reducing agent | |
EP0456460B1 (fr) | Composition cosmétique | |
JP3522378B2 (ja) | 光触媒金属酸化物とトコフェロールを含有する組成物並びに化粧品分野等におけるその使用方法 | |
US5691380A (en) | Stable n-acetylcysteine compositions and methods for treating human skin therewith | |
EP0456458A2 (fr) | Composition cosmétique | |
US20030095959A1 (en) | Topical skin composition | |
KR20070056170A (ko) | 헥사미딘 조성물을 이용한 포유류 각질 조직의 조절 | |
KR20030016202A (ko) | 국소성 피부 조성물 | |
EP0686026A1 (fr) | Combinaisons photoprotectrices synergiques et formulations cosmetiques et dermatologiques les contenant | |
WO2003075880A1 (fr) | Compositions cosmetiques renfermant des triesters d'acide citrique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI NL PT SE |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNILEVER PLC Owner name: UNILEVER N.V. |
|
17P | Request for examination filed |
Effective date: 19930223 |
|
17Q | First examination report despatched |
Effective date: 19940525 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Effective date: 19970827 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19970827 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19970827 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19970827 Ref country code: BE Effective date: 19970827 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19970827 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970827 |
|
REF | Corresponds to: |
Ref document number: 157245 Country of ref document: AT Date of ref document: 19970915 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: UNILEVER PLC Owner name: UNILEVER N.V. |
|
REF | Corresponds to: |
Ref document number: 69221766 Country of ref document: DE Date of ref document: 19971002 |
|
ITF | It: translation for a ep patent filed | ||
NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: UNILEVER N.V. |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2106828 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19971127 Ref country code: PT Effective date: 19971127 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
26 | Opposition filed |
Opponent name: L'OREAL Effective date: 19980526 |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLAW | Interlocutory decision in opposition |
Free format text: ORIGINAL CODE: EPIDOS IDOP |
|
APAC | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPO |
|
APAE | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOS REFNO |
|
APAC | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPO |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
27A | Patent maintained in amended form |
Effective date: 20040714 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI NL PT SE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: DC2A Date of ref document: 20040920 Kind code of ref document: T5 |
|
ET3 | Fr: translation filed ** decision concerning opposition | ||
APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20060525 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20060526 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20060630 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20070526 Year of fee payment: 16 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20070505 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071201 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20070517 Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070505 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20070507 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070507 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20090119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080602 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080505 |